[DP-1111-02CT] A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
ITM Solucin GmbH
Start Date
April 21, 2022
End Date
July 21, 2026
Administered By
Duke Cancer Institute
Awarded By
ITM Solucin GmbH
Start Date
April 21, 2022
End Date
July 21, 2026